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Organobromine compounds such as poly-
brominated diphenyl ethers (PBDEs) are now
largely distributed in the environment because
of their wide use as ﬂame retardants in elec-
tronic equipment, plastics, and textiles.
Several PBDE congeners, their hydroxylated
metabolites, and brominated bisphenol A
analogs induce the estrogen-receptor signal
transduction pathway in vitro and may there-
fore increase the risk of hormone-related dis-
eases (Meerts et al. 2001). Studies in Sweden
have revealed that PBDEs increased in human
breast milk over the last decades (Meironyté
et al. 1999; Norén and Meironyté 2000).
However, in recent years a decrease in con-
centrations has been noted in Sweden (Lind
et al. 2003). A similar decline in levels has not
been reported in plasma samples from people
in North America; to the contrary, limited
data for the U.S. population indicate a steep
increase in PBDE blood concentrations
between 1973 and 2003 (Schecter et al.
2005b). The human levels in North America
are also, in general, considerably higher than
in any other parts of the world.
In the course of a pilot study investigating
possible environmental risk factors of breast
cancer, we analyzed plasma samples obtained
from 110 healthy postmenopausal women
living in the Québec City area (Québec,
Canada) for several persistent organic pollu-
tants. In this article we present the concen-
trations of 4 PBDE, 1 polybrominated
biphenyl (PBB), and 41 polychlorinated
biphenyl (PCB) congeners, the latter for
comparative purposes. We also investigated
the relation between concentrations of these
compounds and anthropometric, demo-
graphic, reproductive, and lifestyle charac-
teristics of participants.
Material and Methods
Population. We recruited a convenience sam-
ple of 110 women at a large mammography
screening clinic located in Québec City. All
women attending the clinic between July
2003 and March 2004 were given a pam-
phlet describing the purpose of the study and
a form to complete (name and coordinates) if
they were interested in participating. A
research nurse later contacted by telephone
each woman who showed interest to verify
her eligibility and schedule an appointment
for a face-to-face interview. Women were eli-
gible if a) they were postmenopausal; b) they
had no history of breast cancer; c) they had
no history of health problems related to
steroid hormone metabolism, hepatic, thy-
roid, or adrenal disease; and d) they had not
taken hormone replacement therapy during
the last 3 months. Women agreeing to partic-
ipate provided informed consent including
authorization for blood sampling and bank-
ing. The protocol of the study was approved
by the Research Ethics Review Board of
Hôpital St-Sacrement – Centre Hospitalier
Afﬁlié Universitaire de Québec. 
During the face-to-face interview, the
research nurse documented participant gyne-
cologic and reproductive histories, current
diseases and drug intake, lifestyle habits, and
the consumption of some food items includ-
ing meat. Women were queried about their
weight and height at 18 years of age. The
research nurse also recorded current anthro-
pometric measures (weight, height, waist cir-
cumference) and collected blood samples
(75 mL) for various biomarker measure-
ments. Blood specimens were collected in
vacutainers with EDTA as the anticoagulant
and were kept on ice until transported by
medical courier to the laboratory at the end
of each morning and afternoon. Blood was
processed within 2–3 hr of collection.
Samples were centrifuged and the plasma
aliquoted and stored at –80°C in glass vials
(prewashed with hexane) until analysis.
Analytical procedure. Plasma samples were
extracted on an Oasis HLB (540 mg; Waters
Corp., Milford, MA, USA) solid phase extrac-
tion (SPE) column according to the method
presented by Sandau et al. (2003). Internal
standards were added to 5 mL of plasma prior
to formic acid (5 mL) and deionized water
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BACKGROUND: Brominated ﬂame retardants, especially polybrominated diphenyl ethers (PBDEs),
have been widely used in North America, but little is known about the level of exposure of human
populations to these compounds.
OBJECTIVES: We set out to assess the internal exposure of postmenopausal Canadian women to
selected organobromine compounds and to investigate factors associated with this exposure.
METHODS: We measured concentrations of four PBDEs, one polybrominated biphenyl, and for
comparative purposes, 41 polychlorinated biphenyl (PCB) congeners in plasma samples from
110 healthy postmenopausal women who were recruited at a mammography clinic in 2003–2004.
RESULTS: PBDE-47 was the major PBDE congener, with a mean (geometric) concentration of
8.1 ng/g lipids and extreme values reaching 1,780 ng/g. By comparison, the mean concentration of
the major PCB congener (PCB-153) was 41.7 ng/g and the highest value was 177 ng/g. PBDEs 47,
99, and 100 were strongly intercorrelated, but weaker correlations were noted with PBDE-153. As
the sum of PBDEs (ΣPBDEs) increased, the relative contribution of PBDE-47 to the ΣPBDEs
increased, whereas that of PBDE-153 decreased. PBDE-153 was the only brominated compound
correlated to PCB-153. PBDE levels were not linked to any sociodemographic, anthropometric,
reproductive, or lifestyle variables documented in the present study. Age and body mass index gain
since the age of 18 years were signiﬁcant predictors of PCB-153 plasma levels.
CONCLUSION: Our results suggest that exposure to PBDE-47 likely occurs through direct contact
with the penta-PBDE formulation, whereas exposure to PBDE-153 may originate in part from the
food chain.
KEY WORDS: brominated flame retardants, polybrominated biphenyls, polybrominated diphenyl
ethers, polychlorinated biphenyls, postmenopausal women, Québec, Canada. Environ Health Perspect
115:1429–1434 (2007). doi:10.1289/ehp.10303 available via http://dx.doi.org/ [Online 24 July 2007](5 mL). The mixture was vortexed for 1 min
and left overnight in the refrigerator. The
HLB column was conditioned with dichloro-
methane (5 mL), followed by 5% methanol
in 0.1 M hydrochloric acid (5 mL). The sam-
ple was then slowly applied to the column at
a ﬂow rate of 0.38 mL/min. After drying the
column with pressurized nitrogen, the sample
was extracted using 10% methanol in
dichloromethane (15 mL). The sample was
evaporated to dryness to ensure that all
methanol was removed from the sample
before it was redissolved in 0.5 mL n-hexane.
The extract was subsequently eluted through
a column containing 1 g activated Florisil
(60–100 mesh; Fisher Scientiﬁc, Pittsburgh,
PA, USA). The fraction containing the
PBDEs was eluted using hexane/dichloro-
methane (9/1; 9 mL). The extraction and
cleanup procedures were automated using a
Rapidtrace Automated SPE workstation
(Zymark Corp., Hopkinton, MA, USA), and
evaporation was performed using a heated vac-
uum evaporator (Rapidvap; Labconco Corp.,
Kansas City, MO, USA). 13C12-PBDE-77 was
used as the internal standard for the PBDEs,
and four different 13C12-PCBs (PCBs 77,
101, 141, and 178) were used as internal
standards for the PCBs (Cambridge Isotope
Laboratories, Andover, MA, USA).
Samples were analyzed on an Agilent
6890N gas chromatograph equipped with
split/splitless injector, Agilent 7683 auto-
sampler, Agilent DB-XLB column (60 m;
0.25 mm i.d., 0.25 µm ﬁlm thickness), cou-
pled with an Agilent 5973N mass spectrom-
eter (Agilent Technologies, Wilmington,
DE, USA). The carrier gas (helium) ﬂow was
0.8 mL/min (ﬂow controlled). The tempera-
ture program was as follows: 100°C (1 min),
10°C/min to 200°C (0 min), 1.5°C/min to
240°C (10 min), 20°C/min to 330°C
(10 min). The injector and transfer lines
were kept at 270°C and 280°C, respectively.
The injection volume was 2 µL, injected in a
pulsed splitless mode.
The mass spectrometer was operated in
selected ion monitoring mode, using electron
capture negative ionization with methane
(99.97% purity) as the reagent gas. The ion
source and quadropole temperatures were set
to 150°C and 103°C, respectively. Masses 79
and 81 were monitored for all brominated
compounds. For PCBs, the molecular ion
and M-2 fragment ion were monitored as
the target and conﬁrmation ions. The target
ion was employed for quantiﬁcation, and the
confirmation ion from the same isotopic
cluster was used to confirm the identity of
the compound.
We determined concentrations of total
cholesterol, free cholesterol, triglycerides,
and phospholipids in plasma samples by
enzymatic methods. The total plasma lipid
concentration was calculated according to the
equation proposed by Akins et al. (1989).
Quality assurance/quality control. The
accuracy of the analytical method was assured
through analysis of certiﬁed reference materi-
als and participation in international interlab-
oratory comparison programs both for PCBs
and PBDEs. In addition, the precision was
monitored by analyzing 15 samples from a
control serum pool. The analysis of the serum
pool samples gave reproducible results for the
PBDEs. For PBDE-47, the mean concentra-
tion of the control pool samples was
422 ng/L and the coefficient of variation
(CV) was 11%. For comparison, the mean
PCB-153 concentration was 328 ng/L and
the CV was 6%. The accuracy of the PBDE
and PCB analyses was assured through the
quantification of the NIST SRM (standard
reference material) 1589a (National Institute
of Standards and Technology, Gaithersburg,
MD, USA). The mean concentration of
PBDE-47 measured in this reference material
was 193 ng/L, a value 12% above the mean
reference value of 172 ng/L (range, 162–182
ng/L). For PBDE-99, we obtained a mean
value of 48 ng/L, which is 20% above the ref-
erence value of 39.9 ng/L (range, 34.7–45.1
ng/L). For PBDE-100 we obtained the same
value as the reference value (i.e., 25 ng/L).
For PCB-153, the mean concentration was
833 ng/L, which is 11% below the reference
value of 936 ng/L (range, 891–981 ng/L).
The average concentration of PBDE-47 in
blank samples was 16 ng/L (SD, 5 ng/L). For
PBDEs 99 and 100, the blank values were
10 and 2 ng/L, respectively. PBDE-153,
PBB-153, and PCB-153 were not detected in
blanks. The blank values were subtracted
from all concentrations before the results
were reported. The recovery rates for
13C12-PBDE-77 were between 40 and 90%.
The recovery rates for 13C12-PCBs were
between 50 and 95%. The limit of detection
(LOD) was 4 ng/L for PBDE-47 and 2 ng/L
for the other PBDE congeners and PBB-153.
The LOD ranged from 3 to 5 ng/L for PCB
congeners.
Statistics. We used the SPSS software
package (v. 11.0; SPSS, Chicago, IL, USA) to
perform all statistical analyses. PBDEs and
PCBs plasma concentrations were log-trans-
formed before correlation and multiple linear
regression analyses because the distributions of
values were skewed to the right. We per-
formed multiple linear regression analyses to
determine predictors of PBDE and PCB
plasma levels. Independent variables of inter-
est for these analyses were age, body mass
index (BMI), BMI gain since 18 years of age,
parity and breast-feeding history, meat con-
sumption, alcohol consumption, and smoking
habits. Results from multiple linear regres-
sions were analyzed for the detection of multi-
colinearity problems. Statistical tests were
two-sided, and a conﬁdence level of 0.05 was
used as the criteria for statistical signiﬁcance.
Results
The characteristics of participating women
are shown in Table 1. The mean age of the
110 women was 58.3 years (range, 48–76
years). All were Caucasian except for one
woman of Mediterranean origin. Twenty-ﬁve
percent of the women were nulliparous, and
13% had had ≥ 4 children. Of the 83 parous
women, 40 (48.2%) never breast-fed. Only
Sandanger et al.
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Table 1. Selected characteristics of the 110 postmenopausal women, Québec, Canada.
Characteristic No. (%) Mean ± SD Range
Age (years) 58.3 ± 5.6 48 to 76
Weight (kg) 68.7 ± 14.0 44.8 to 133.0
Height (cm) 160 ± 5.2 146 to 172
BMI (kg/m2) 27.0 ± 5.4 17.2 to 51.3
BMI gain since 18 years of age (kg/m2) 6.4 ± 5.4 –14.7 to 28.0
No. of children 1.9 ± 1.4 0 to 5
Cumulative breast-feeding duration (weeks) 12.9 ± 26.5 0 to 124.3
Alcohol consumption (no. of drinks/day) 0.46 ± 0.56 0 to 3
Meat consumption (g/day) 59.7 ± 46.2 1.8 to 220.0
Smoking
Current 8 (7.3)
Ever 54 (49.1)
Never 48 (43.6)
Level of education
Primary 9 (8.2)
High school 26 (23.9)
College or university 75 (68.2)
Table 2. Lipid weight concentrations (ng/g lipids) of
selected organobromine compounds in plasma
samples from 110 postmenopausal women, Québec,
Canada.
Percent
Compounds Mean GM Range detected
PBDEs
PBDE-47 39.0 8.10 0.81–1,780 100
PBDE-99 11.6 1.40 < 0.40–716 90
PBDE-100 6.79 1.10 < 0.40–366 83
PBDE-153 5.38 1.35 < 0.40–198 96
ΣPBDEs 63.7 13.4 0.81–3,060 100
PBB-153 0.46 0.22 < 0.40–20.1 30
A value equal to one-half the LOD was substituted for non-
detects to calculate mean values.7.3% of participants were current smokers,
and they smoked an average of 12 cigarettes/
day (range, 3–30). The vast majority (93.6%)
of women had consumed alcohol during the
year before the interview, and 30% had done
so the day before the interview. Mean alcohol
intake was one-half of a drink per day, rang-
ing from 0 to 3 drinks/day. More than two-
thirds of women had reached the college or
university level of education. In general,
women with more education tended to con-
sume more alcohol, to breast-feed more, and
had a lower BMI.
The concentrations of the four PBDE
congeners and PBB-153 are shown in
Table 2. PBDE-47 was the congener with the
highest geometric mean (GM) concentration
(8.1 ng/g lipids) and was detected in all sam-
ples. It was the major congener in 96.4% of
the participants (106/110). PBDEs 99, 100,
and 153 were also frequently detected
(≥ 83% of samples), but they were present in
much lower concentrations (GM concentra-
tions ranging from 1.1 to 1.4 ng/g lipids).
PBDE-153 was the dominant congener in
3.6% of the participating women (4/110).
PBB-153 was detected in only 30% of the
samples, at levels considerably lower than
those of the PBDEs. The arithmetic means of
untransformed values were considerably
higher than the median values for the PBDEs
due to three women with very high levels.
The maximum value observed for PBDE-47
was 1,780 ng/g lipids (Table 2). This concen-
tration is 10 times higher than the highest
value observed for PCB-153 (177 ng/g lipids),
which is the most abundant PCB congener
(Table 3). Several other brominated com-
pounds were also detected in the samples with
elevated values. These were not identiﬁed due
to lack of standards.
As mentioned above, distributions of
PBDE and PCB congener concentrations were
skewed right and values were log-transformed
prior to performing statistical analyses. Three
women were still considered outliers on the
basis of their log-transformed ΣPBDE (sum
of PBDEs) concentrations that exceeded the
mean value plus 4 SDs. These women were
removed before performing additional statis-
tical analyses that aimed at identifying factors
associated with PBDE concentrations.
PBDEs 47, 99, and 100 were highly inter-
correlated (Pearson’s r > 0.86; p < 0.001;
Figure 1A, B). PBDE-153 behaved differently
from the other PBDEs, as it was not as highly
correlated to the other congeners; for exam-
ple, the correlation coefficient between
PBDE-153 and PBDE-47 was 0.53 (p <
0.001; Figure 1C). PBDEs 47, 99, and 100
were not correlated to PCB-153. Only
PBDE-153 was weakly correlated to
PCB-153 (r = 0.19; p = 0.046; Figure 1D).
The relative contribution of PBDE-47 to the
ΣPBDEs increased with the increasing
ΣPBDEs (Figure 2A), as opposed to
PBDE-153, which represented a decreasing
proportion of the ΣPBDEs as the ΣPBDEs
increased (Figure 2B).
The lipid-adjusted concentrations of
PCB congeners that were detected in ≥ 50%
of the samples are presented in Table 3.
Congeners that were detected in < 50% of
the samples were PCBs 28, 44, 49, 52, 70,
82, 87, 101, 110, 128, 151, 158, 169, 171,
191, 205, and 208. These congeners are not
discussed further and are not included in
Organobromine compounds in plasma of Québec women
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Table 3. Lipid weight concentrations (ng/g lipids) of
PCB congeners in plasma samples from 109 post-
menopausal women, Québec, Canada.
Percent
Congener Mean GM Range detected
PCB-74 10.8 9.41 <3.80–50.5 97
PCB-99 9.14 6.66 <1.41–64.3 94
PCB-105 2.30 1.80 <1.00–13.4 69
PCB-118 13.1 11.2 3.81–69.9 100
PCB-138 25.9 22.7 5.45–101 100
PCB-146 4.72 4.01 1.55–33.8 100
PCB-153 47.1 41.7 14.4–177 100
PCB-156 5.36 4.77 2.15–24.7 100
PCB-163 17.1 14.5 5.39–124 100
PCB-167 1.60 1.30 < 0.96–8.52 66
PCB-170 12.9 11.4 5.57–65.2 100
PCB-172 1.62 1.30 < 0.72–11.5 64
PCB-177 1.76 1.46 < 0.80–8.68 72
PCB-178 2.29 1.80 < 0.94–19.6 81
PCB-180 40.4 34.7 1.39–206 100
PCB-183 3.09 2.71 <1.30–9.3 96
PCB-187 9.00 7.56 2.26–62.2 100
PCB-194 7.35 6.36 < 0.57–42.1 99
PCB-195 1.20 1.01 < 0.72–5.44 50
PCB-196 2.10 1.78 < 0.80–9.09 84
PCB-199 2.64 2.20 < 1.06–17.8 88
PCB-203 4.53 4.04 < 0.82–21.1 99
PCB-206 2.47 2.11 < 0.94–13.3 90
PCB-209 1.19 0.92 < 0.60–8.19 60
ΣPCBs 229 204 93.1–1,010
Only congeners detected in > 50% of the samples are
listed. A value equal to one-half of the LOD was substituted
for nondetects to calculate mean values. n = 109 (analytical
problems were encountered with one sample).
Figure 1. Correlations between plasma concentrations of PBDE-47 and PBDE-99 (A; Pearson’s r = 0.86;
p < 0.001), PBDE-153 (B; Pearson’s r = 0.53; p < 0.001), and PBDE-100 (C; Pearson’s r = 0.90; p < 0.001; n = 110
for each) and between PBDE-153 and PCB-153 (D; Pearson’s r = 0.19; p < 0.046; n = 109) in postmenopausal
women from Québec, Canada.
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Figure 2. Correlations between plasma concentrations of the ΣPBDEs and relative contributions of PBDE-47
(A; Pearson’s r = 0.22; p < 0.026) and PBDE-153 (B; Pearson’s r = 0.49; p < 0.001) to the ΣPBDE levels in 110
postmenopausal women from Québec, Canada.
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1.0ΣPCB values. The dominating PCB con-
gener was PCB-153, with a GM concentra-
tion of 41.7 ng/g lipids (range, 14.4–177),
followed by PCBs 180, 138, 163, and 118.
The GM ΣPCB level was 204 ng/g lipids
(range, 93.1–1,010). Concentrations of the
major PCB congeners and of total PCBs
were highly intercorrelated (data not shown),
and the major congener, PCB-153, was used
in the statistical analyses as a surrogate of
PCB exposure.
We tested age, BMI, BMI gain since the
age of 18 years, parity, cumulative breast-
feeding duration, meat consumption, alcohol
consumption, and smoking habits for associ-
ations with levels of PBDEs and PCBs
(PCB-153 as the surrogate). None of these
factors was related to the plasma concentra-
tions of PBDEs. Current BMI and BMI gain
since 18 years of age were negatively corre-
lated to PCB-153 plasma concentrations
(current BMI: r = –0.40, p < 0.001; BMI
gain: r = –0.54, p < 0.001), whereas age was
positively related to PCB-153 concentrations
(r = 0.23, p = 0.015). Multiple linear regres-
sion analyses revealed that PCB-153 levels
were positively associated with age (p = 0.01)
and negatively associated with BMI gain
(p < 0.001). Current BMI was also positively
related to PCB-153 concentrations in the
ﬁnal model, although the association did not
reach statistical signiﬁcance (p = 0.06). The
total model explained 34% of the variance in
PCB-153 concentrations (Table 4).
Discussion
We analyzed plasma samples collected from
postmenopausal women residing in the
Québec City area for PBDEs, which along
with other brominated flame retardants are
emerging as contaminants of interest because
of their persistence and toxicologic properties
similar to those of PCBs. Although mean
concentrations of PBDE congeners were
much lower than those of major PCB con-
geners, a few women displayed high PBDE
concentrations that exceeded those of major
PCBs by an order of magnitude, suggesting
that sources of direct exposure are still present
in the home and the workplace (Birnbaum
and Hubal 2006).
Comparative data from studies con-
ducted in the United States and Europe are
presented in Table 5. For these comparisons
we have not distinguished between different
age groups or sex because there have been no
previous reports of levels of PBDEs increas-
ing with age or being different in men and
women (Birnbaum and Hubal 2006).
Because PBDEs are lipophilic compounds,
we present data on a lipid basis to ensure
their comparability, whatever the biological
sample analyzed (whole blood, serum,
plasma, or adipose tissue). From the data
presented in Table 5, it is clear that the levels
of PBDEs in the women from Québec are
substantially (up to 10-fold) higher than the
levels in Europe. The levels of PBDEs in our
sample of women from Québec clearly sup-
port previous findings of concentrations
being considerably higher in North America
compared with other parts of the world. The
Québec levels do seem a little lower than
those in the United States (Table 5).
In our group of Québec women,
PBDE-47 is the dominating congener, and
that also seems to be the case in the samples
from the United States (Table 5). In
European samples, however, PBDE-153 is
often the dominating congener (Fängström
et al. 2005; Johnson-Restrepo et al. 2005;
Morland et al. 2005; Schecter et al. 2003).
This difference in congener patterns between
Europe and North America may be explained
by differences in the use of penta-PBDE
formulations, in which PBDE-47 is a main
constituent. The European penta-PBDE
technical mixture Bromkal 70-5DE was not
used as extensively and has been banned for a
longer period of time compared to the North
American penta-PBDE mixture DE-71
(Birnbaum and Staskal 2004). Exposure to
DE-71 is still occurring in North America;
therefore, people are being exposed to
PBDE-47 on a day-to-day basis. In Europe,
exposure to the penta-PBDE formulation has
declined and is probably rare nowadays. The
PBDE congener pattern in plasma of people
exposed several years ago to a penta-PBDE
mixture but with little current exposure to
this mixture is expected to shift in favor of
the more persistent congeners. The estimated
half-life (t1/2) of PBDE-153 (t1/2 = 6.5 years),
a minor component of the penta-PBDE and
octa-PBDE mixtures (La Guardia et al.
2006), is three times longer than that of
PBDE-47 (t1/2 = 1.8 years); therefore, over
time PBDE-153 should become the domi-
nant one (Geyer et al. 2004; Hagmar et al.
2000; Thuresson et al. 2006). We (as most
other authors) did not measure PBDE-209 in
the plasma samples of participants. A deca-
PBDE mixture, mainly composed of
PBDE-209, has replaced the penta-PBDE
mixture in several applications in Europe.
PBDE-209 has been reported to be the major
congener in human serum in one study
(Inoue et al. 2006). Although it is unlikely
that PBDE-209 would be a dominant con-
gener in North American samples, it might
be an important one in European samples,
along with lower brominated congeners
resulting from its biotransformation.
Considering that PCB levels are age and
sex dependent, care should be exerted when
comparing PCB-153 levels with those in
other studies. Nevertheless, it seems clear
from data in Table 5 that PCB-153 levels are
lower in North America than in Europe. In a
recent Canadian study, Tsuji et al. (2006)
reported GM PCB-153 concentrations to be
50.2, 53.6, and 27.0 ng/g lipids in women
from Fort Albany (Ontario), Kashechewan
(Ontario), and Hamilton (Ontario), respec-
tively. The first two groups were composed
Sandanger et al.
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Table 4. Multiple linear regression analysis of log-transformed PCB-153 concentrations (ng/g lipids) in
plasma samples from 109 postmenopausal women, Québec, Canada.
Unstandardized Standardized 
BS E β p-Value
Age at interview (years) 0.007 0.003 0.202 0.012
Current BMI (kg/m2) 0.013 0.007 0.336 0.058
BMI gain since 18 years of age (kg/m2) –0.031 0.007 –0.827 < 0.001
Model adjusted R2 = 0.335; n = 109 (analytical problems were encountered with one sample). 
Table 5. Comparison of PBDE and PCB-153 levels in the present study with concentrations from other studies conducted elsewhere in the world.
Reference PBDE-47 PBDE-99 PBDE-100 PBDE-153 PCB-153 Medium Age Sex Country No.
Present study  8.1 1.4 1.1 1.4 41.7a Plasma 48–76 Female Canada 110
Schecter et al. 2005b 12.8 3.2 2.6 3.6 Blood 22–91 Both United States 39
Sjödin et al. 2004  34 11 5.9 7.3 35 Serum ? Both United States Pool
Johnson-Restrepo et al. 2005 29.3 10.3 12.0 < 1 35.2b Adipose tissue 18–51 Both United States 52
Weiss et al. 2006 0.91 0.20 0.29 1.1 260 Serum 52–81 Female Sweden 53
Thomas et al. 2006 0.82 < 0.16 0.76 1.7 41 Serum 22–80 Both United Kingdom 154
Fängström et al. 2005 1.3 0.33 0.51 1.0 430 Serum ? Female Faroes 57
Naert et al. 2006 0.88 0.47 0.72 2.40 274 Adipose tissue 19–84 Both Belgium 53
All levels are either GMs or medians and are expressed on a lipid basis (ng/g lipids).
an = 109. bSum of hexa-chlorinated congeners.of First Nation women. Plasma concentra-
tions measured in Québec City women are
slightly lower than those measured in native
women from Ontario but higher than those
determined in non-native women from the
same province.
Correlation analyses revealed that
PBDE-153 was only moderately correlated
to PBDE-47 (Figure 1D). We also observed
that the contribution of PBDE-47 to
ΣPBDEs increased with increasing concen-
trations of ΣPBDEs, whereas the reverse was
true for the contribution of PBDE-153 to
ΣPBDEs (Figure 2). These results again sug-
gest that the sources of exposure to
PBDE-153 might be different from those of
the other PBDEs. Individuals with high
PBDE plasma concentrations and a pattern
of congeners dominated by PBDE-47 may
have been directly exposed to the DE-71
mixture in which PBDE-47 and PBDE-99
are the dominating compounds. Inhalation
and dermal contact with technical mixtures
of PBDEs in commercial products may con-
tribute substantially to exposure (Sjödin
et al. 2004), and several studies in North
America have reported dust and indoor
exposure to be significant sources of PBDE
exposure (Schecter et al. 2005a; Stapleton
et al. 2005; Wu et al. 2007). Interestingly,
some studies have reported higher plasma
levels of PBDEs in children than in adults
(Fischer et al. 2006; Thomsen et al. 2002),
which may reﬂect the elevated dust exposure
of toddlers (Jones-Otazo et al. 2005).
In individuals with lower PBDE plasma
levels, the following lines of evidence indi-
cate that exposure may originate in part from
food consumption. We observed that the
proportion of total PBDEs represented by
PBDE-153 increases as total PBDE concen-
trations decrease. Similar to PCBs, weather-
ing of PBDEs in the environment should
lead to mixtures that are enriched in long-
lived congeners such as PBDE-153 and
lower in less persistent, lower-brominated
congeners. The weak but statistically signiﬁ-
cant correlation observed between PCB-153
and PBDE-153 levels supports the interpre-
tation of a common source of exposure to
these compounds. Because exposure to PCBs
is mainly through food consumption, this
supports our contention that PBDE-153
exposure also occurs in part through food
consumption. We did not conduct a com-
plete dietary assessment of participants, but
our questionnaire included questions on the
consumption of a limited number of food
items, including meat. We did not ﬁnd any
relation between meat consumption and
plasma concentrations of PBDEs or PCBs.
Hence, our results differ from those of Wu
et al. (2007), who recently reported a posi-
tive association between meat consumption
and PBDE concentrations in breast milk
samples from 46 ﬁrst-time mothers living in
the greater Boston (Massachusetts) area. The
consumption of fish has been linked to
higher plasma PCB levels in Great Lakes ﬁsh
consumers (Humphrey et al. 2000) and in
postmenopausal U.S. women (Moysich et al.
2002; Wolff et al. 2005). It would have been
interesting to examine relations of plasma
PCBs and PBDEs to fish consumption in
our study; unfortunately, we did not docu-
ment fish consumption in our group of
Québec women.
To our knowledge, no study conducted to
date has found signiﬁcant relations between
PBDE concentrations in biological samples
and age, BMI, parity, breast-feeding duration,
or lifestyle habits. In contrast, we identiﬁed
age and BMI as significant predictors of
plasma PCB levels in our sample of Québec
women. Similar associations had previously
been reported in the two U.S. studies men-
tioned above (Moysich et al. 2002; Wolff
et al. 2005). The lack of association noted
between PBDE levels and age or BMI again
supports the idea that the sources of exposure
are different for PCBs and PBDEs. The lack
of age factor might be explained by the rela-
tively recent introduction of PBDEs, different
exposure pathways, and the greater metabo-
lism and elimination of PBDEs compared
with PCBs (Johnson-Restrepo et al. 2005).
The final multiple linear regression
model for plasma PCB-153 concentrations
included age, current BMI, and BMI gain
since 18 years of age as predictors and
explained 34% of the variance (Table 4).
Including BMI gain in the model increased
the R2 value by 13% compared with the
model containing only age and current BMI
as independent variables (data not shown).
Including BMI gain in the model also
changed the direction of the association
between current BMI and PCB-153 levels
from negative to positive. Wolff et al. (2005)
obtained a similar multivariate model that
explained 30% of the variance in plasma
PCB concentrations of 999 postmenopausal
women on Long Island, New York. The
major influence of BMI gain in our model
could be explained by corresponding changes
in the volume of the adipose tissue compart-
ment, which is the major site of storage for
PCBs and other lipophilic compounds. The
greater the increase in the volume of the adi-
pose tissue compartment, the greater the
dilution of PCB residues and the lower their
plasma concentration.
PBB-153 was detected in only 30% of
the samples and was neither correlated to
PBDEs nor to PCB-153. Levels of PBB-153
were also considerably lower than those of
the PBDEs, as previously reported for the
U.S. population (Sjödin et al. 2004).
One limitation of our study is the use of a
convenience sample of postmenopausal
women instead of a random population sam-
ple. It is likely that women recruited in breast
cancer screening clinics are not representative
of the general population of women on several
characteristics. Compared with women from
the general population, women in our study
were more educated and smoked less than
women from the general population. This
would not however compromise the validity
of our results, although they might be less
amenable to generalization. Our study pro-
vides a ﬁrst estimate of PBDE body burden in
Canadian postmenopausal women. The
major strengths of our study are its relatively
large sample size and the extensive quality
control–quality assurance procedures imple-
mented for the analytical work.
In summary, the concentrations of
organobromine compounds in plasma sam-
ples of Canadian women were slightly lower
than those in the United States. However, the
fact that the GM concentration of PBDE-47
is only 6 times lower than that of PCB-153
but the arithmetic means are comparable,
clearly indicates the need to monitor PBDEs
in human populations on a regular basis. The
reason for the extreme levels determined in
some women needs to be elucidated; there is
also a need to identify the most important
sources of human exposure to PBDEs in the
general population.
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